{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["21(1)"],"submitter":["Booth SW"],"funding":["Oxford Experimental Cancer Centre"],"pubmed_abstract":["<h4>Background</h4>This Phase 2a dose expansion study was performed to assess the safety, tolerability and preliminary efficacy of the maximum tolerated dose of the oral histone de-acetylase (HDAC) inhibitor CXD101 in patients with relapsed / refractory lymphoma or advanced solid organ cancers and to assess HR23B protein expression by immunohistochemistry as a biomarker of HDAC inhibitor sensitivity.<h4>Methods</h4>Patients with advanced solid-organ cancers with high HR23B expression or lymphomas received CXD101 at the recommended phase 2 dose (RP2D). Key exclusions: corrected QT > 450 ms, neutrophils < 1.5 × 10<sup>9</sup>/L, platelets < 75 × 10<sup>9</sup>/L, ECOG > 1. Baseline HR23B expression was assessed by immunohistochemistry.<h4>Results</h4>Fifty-one patients enrolled between March"],"journal":["BMC cancer"],"pagination":["851"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8306282"],"repository":["biostudies-literature"],"pubmed_title":["A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma."],"pmcid":["PMC8306282"],"pubmed_authors":["Rees G","Kazmi F","Campo L","Soilleux E","Kesavan M","La Thangue N","Whittaker J","Booth SW","Collins GP","Royston D","Hildyard C","Eyre TA","Middleton MR","Kerr D","Wang LM"],"additional_accession":[]},"is_claimable":false,"name":"A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma.","description":"<h4>Background</h4>This Phase 2a dose expansion study was performed to assess the safety, tolerability and preliminary efficacy of the maximum tolerated dose of the oral histone de-acetylase (HDAC) inhibitor CXD101 in patients with relapsed / refractory lymphoma or advanced solid organ cancers and to assess HR23B protein expression by immunohistochemistry as a biomarker of HDAC inhibitor sensitivity.<h4>Methods</h4>Patients with advanced solid-organ cancers with high HR23B expression or lymphomas received CXD101 at the recommended phase 2 dose (RP2D). Key exclusions: corrected QT > 450 ms, neutrophils < 1.5 × 10<sup>9</sup>/L, platelets < 75 × 10<sup>9</sup>/L, ECOG > 1. Baseline HR23B expression was assessed by immunohistochemistry.<h4>Results</h4>Fifty-one patients enrolled between March","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jul","modification":"2026-05-07T23:54:55.056Z","creation":"2022-02-11T00:20:49.253Z"},"accession":"S-EPMC8306282","cross_references":{"pubmed":["34301221"],"doi":["10.1186/s12885-021-08595-w"]}}